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Abstract 14 
Non-islet-cell tumor hypoglycemia (NICTH) is a rare paraneoplastic phenomenon well described in dogs 15 
and humans. Tumors associated with NICTH secrete incompletely processed forms of insulin-like growth 16 
factor-II (IGF-II), commonly named big IGF-II. These forms have increased bioavailability and interact with 17 
the insulin and IGF-I receptor causing hypoglycemia and growth-promoting effects. Immunoassays 18 
designed for human samples have been used to measure canine IGF-I and -II, but they possess some 19 
limitations. In addition, there are no validated methods for measurement of big IGF-II in dogs. In the 20 
present study, a targeted PRM MS-based method previously developed for cats has been optimized and 21 
applied to simultaneously quantify the serum levels of IGF-I, IGF-II, and IGFBP-3, and for the first time, 22 
the levels of big IGF-II in dogs. This method allows the absolute quantification of IGF proteins using a 23 
mixture of QPrEST™ proteins previously designed for humans. The method possesses good linearity and 24 
repeatability, and has been used to evaluate the IGF-system in a dog with NICTH syndrome. In this dog, 25 
the levels of big IGF-II decreased by 80% and the levels of IGF-I and IGFBP-3 increased approximately 20 26 
and 4 times, respectively, after removal of the tumor. 27 
 28 
 29 
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INTRODUCTION 32 
Non-islet-cell tumor hypoglycemia (NICTH) is a rare paraneoplastic phenomenon that is well described in 33 
both dogs and humans. NICTH denotes the syndrome of hypoglycemia produced by or associated with 34 
any neoplasm other than an insulinoma.1 In most of the human cases, this syndrome is derived from an 35 
overproduction of insulin-like growth factor-II (IGF-II) by the tumor, including mature IGF-II or 36 
incompletely processed forms of IGF-II, that are referred to as big IGF-II.2-4 In humans and animals, IGF-I 37 
and -II are both important regulators of growth and metabolism, and circulate bound to one of a family 38 
of six insulin-like growth factor-binding proteins (IGFBP 1-6), that modulate IGF-bioavailability.5 Of the 39 
IGFBPs, IGFBP-3 is the most abundant in the circulation and transports more than 75% of IGF-I or -II in a 40 
ternary complex with an acid-labile subunit (ALS).6 The large size of this complex (∼ 150 kDa) limits the 41 
passage of IGFs across the capillaries,7 thus prolonging their half-life from a few minutes, to hours or 42 
days, and determining their circulating concentrations.8 IGFs and IGFBPs also form binary complexes (40-43 
50 kDa) that are sufficiently small to cross the capillary membrane and gain access to most tissues.9 In 44 
NICTH cases, big IGF-II can contribute up to 60% of the total circulating IGF-II concentration. It has been 45 
proposed that impaired proteolytic processing is due to the absence of glycosylation in the big 46 
isoforms,10 as well as the exceeded proteolytic capacity of the tumor cells.11 Moreover, although big IGF-47 
II isoforms bind to IGFBPs with the same affinity as mature IGF-II, ternary complexes are formed less 48 
readily, and the formation of binary complexes is promoted.12,13 Finally, some big IGF-II isoforms have 49 
reduced affinity for the IGF-II receptor, which may decrease its degradation and thereby increase 50 
bioavailability.14 All of these effects increase the amount of bioavailable IGF-II and big IGF-II, that can 51 
interact with the insulin and IGF-I receptor causing hypoglycemia and growth-promoting effects.1,15 52 
In normal circumstances, growth hormone (GH) induces synthesis of IGF-I and ALS by the liver. In 53 
addition, serum IGFBP-3 increases as a result of increased availability of ternary complex formation.16 In 54 
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vitro studies demonstrate that IGF-I and IGF-II have inhibitory effects on pituitary GH.17  Consistent with 55 
a negative feedback by big IGF-II forms in NICTH,  patients have suppressed IGF-I, ALS and IGFBP-3 which 56 
increase in response to growth hormone treatment.18,19 Total IGF-II may be either within the reference 57 
interval, decrased or increased in patients with NICTH.1 Currently, reduced circulating IGF-I 58 
concentrations are routinely used in the investigation of suspected NICTH.1,20 However, since IGF-I may 59 
be suppressed in severe catabolic illness,21 measurement of big IGF-II is more specific for the disorder.  60 
Simultaneous measurements of IGF-I, IGF-II, big IGF-II and IGFBP-3 could aid in diagnosing NICTH as well 61 
as improving understanding of the GH-IGF-system in health and disease. To the best of our knowledge, 62 
the serum concentrations of big IGF-II protein in dogs have never been measured before. 63 
Canine IGF-I, IGF-II and IGFBP-3 concentrations have been measured using a variety of methods. 64 
Radioimmunoassays (RIA) have been used to study the levels of IGF-I and -II,22-25 enzyme-linked 65 
immunosorbent assays (ELISA) to measure the levels of IGF-I,26 and Western Ligand Blotting (WLB) to 66 
evaluate the levels of IGFBP-3.22-23 However, all these methods have limitations. The use of human 67 
immunoassays for analysis of samples from other species can result in weak reactivity or unwanted 68 
cross-reactivity. Moreover, IGFBPs can interfere with IGFs measurements, causing both false high or low 69 
values depending on the assay.27 In addition to this problem, data available from the College of American 70 
Pathologists proficiency testing program for IGF-I demonstrated that interlaboratory variability of human 71 
IGF-I immunoassays has an RSD up to 33.5%,28 and there is no available reference standard for 72 
quantification of canine IGF-II. 73 
To solve these problems, and due to the good capabilities offered by liquid chromatography (LC) coupled 74 
to mass spectrometry (MS) in other fields,29 MS-methods have been proposed to measure IGFs 75 
proteins.30 In comparison to RIA, ELISA and WLB, LC-MS-methods require smaller volumes of samples 76 
and allow the unambiguous identification and quantification of multiple proteins in a single experiment. 77 
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Published studies have applied this methodology to quantify IGF-I,28,31-33 or IGF-I, IGF-2, IGFBP-2 and 78 
IGFBP-3 simultaneously in humans,34 as well as in other species.35,36 In most of these experiments, and 79 
due to the wide dynamic range of protein concentrations, a tedious and/or time-consuming step of 80 
protein depletion is necessary to remove the most abundant proteins and to avoid the suppression of 81 
the signal of the least abundant. To achieve this, different protocols have been developed using 82 
acetonitrile,28 SPE columns,32 or specific antibodies for protein purification.31 After sample preparation, 83 
the analysis of the proteins is often performed using a triple quadrupole MS spectrometer, where a 84 
peptide (precursor) is targeted for its fragmentation, and the quantification is performed at the MS/MS 85 
level using 3 to 6 transitions previously selected (commonly known as selected/multiple reaction 86 
monitoring (SRM/MRM)).37 However, the development of more advanced mass spectrometers has 87 
enabled the use of other methods for quantification, such as the parallel reaction monitoring (PRM).38,39 88 
This method is mainly performed using quadrupole-Orbitrap mass spectrometers, where a precursor is 89 
selected, all transitions are measured, and the selection of fragments for quantification is done post-90 
acquisition. Since full MS/MS spectra of the targeted peptides are acquired with high resolution and high 91 
mass accuracy, a PRM-based targeted method of protein quantification is highly selective and 92 
specific,40,41 making it a very good method for targeted proteomics in complex matrices such as serum or 93 
plasma.42 In addition, the great capabilities of this instrumentation have recently allowed the analysis of 94 
different IGFs in feline serum without extensive sample preparation.43 In targeted MS-methods, heavy 95 
isotope-labelled peptides or full-length proteins are used for quantification of the endogenous proteins, 96 
which allow the comparison of their signals with the internal standards that are spiked into the samples 97 
during processing. The most commonly used peptides contain arginine or lysine with 13C and 15N isotope 98 
at the C-terminal end, and the most used synthetic proteins are QconCAT and PSAQ.44,45 Other synthetic 99 
proteins are available, such as the QPrEST™ proteins.46 QPrEST™ proteins are 50-150 amino acid-long 100 
segments of human proteins with heavy isotope-labelled (15N, 13C) lysine and arginine, covering more 101 
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than 80% of the human protein-coding genes.47 However, these proteins are rarely used to quantify 102 
human and non-human proteins. 103 
To the best of our knowledge, no MS-based method has been published that quantifies canine IGF-I, IGF-104 
II, big IGF-II and IGFBP-3 simultaneously. Therefore, the aim of this study is to optimize and use a 105 
previously targeted PRM MS-based method developed for cats, to absolutely quantify the levels of these 106 
IGF proteins and, for the first time, the levels of big IGF-II in dogs. The method was applied to diagnose 107 
and monitor a recent case of canine NICTH that was successfully managed surgically. 108 
MATERIALS AND METHODS 109 
Chemicals and reagents 110 
Acetonitrile (ACN), formic acid (FA) and trifluoroacetic acid (TFA) were purchased from Merck 111 
(Darmstadt, Germany). Ammonium bicarbonate (NH4HCO3), urea, dithiothreitol (DTT) and iodoacetamide 112 
(IAA) were obtained from Sigma-Aldrich (St. Louis, MO, USA). For the tryptic digestion, trypsin 113 
(sequencing grade modified, Promega, Madison, WI, USA) was used. Ultrapure water was prepared by 114 
the Milli-Q water purification system (Millipore, Bedford, MA, USA). 115 
Canine serum samples 116 
Healthy dogs (n=7) were sampled at the University Animal Hospital, Swedish University of Agricultural 117 
Sciences, Uppsala (Sweden), as well as in a smaller private clinic. All dogs were considered healthy by 118 
their owners and after a clinical examination by a veterinarian. Since weight is strongly related to IGF-I 119 
concentrations,48-49 dogs were selected to represent a wide range of size. The breeds included Labrador 120 
Retriever, Australian Shepard, Russkiy Toy, German Shepard, Cane corso, Border Collie and Mixed breed. 121 
Age ranged from 1-9 years with median (IQR) of 4 (2-7) and weight between 2.4-46 kg with median (IQR) 122 
of 24 (14-36). There were 1 spayed female, 3 intact females and 3 intact males. The study was approved 123 
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by the Swedish Animal Ethics Committee (no. C193/14) and all owners provided written informed 124 
consent. Blood was drawn into plain tubes and centrifuged within 30-60 minutes. Serum was either 125 
frozen in -20°C or sent to the laboratory by post at ambient temperatures. All blood samples arrived 126 
within 24 hours after sampling. Blood samples from a dog with suspected NICTH syndrome, before and 127 
after tumor removal, were also used for validation. 128 
Protein standards 129 
To be able to match tryptic peptides in QPrEST™ proteins with dog sequences, Clustal Omega (1.2.4)50 130 
was used for sequence alignment of Homo sapiens and Canis familiaris amino acid (aa) sequences 131 
(Figure 1). QPrEST™-containing peptides matching with Canis familiaris IGF-II (Cat. Number 22489) and 132 
IGFBP-3 (Cat. Number 23429), with ≥99% isotopic purity and ≥80% peptide purity, were provided by 133 
Atlas Antibodies (Stockholm, Sweden). For IGF-I, the peptide GPETLCGAELVDALQFVCGDR synthesized 134 
with heavy-labelled (15N, 13C) lysine and arginine (≥99% isotopic purity and ≥95% peptide purity) was 135 
purchased from New England Peptides (Gardner, MA, USA). The uniqueness of the sequences to the 136 
targeted proteins was checked using the “peptide search” tool of the Uniprot database against Canine 137 
proteins, and using Skyline. 138 
In-solution tryptic digestion 139 
The protein content in dog sera was measured using the Bradford protein assay (Bio-Rad Laboratories, 140 
Hercules, CA, USA). For normalization, a volume of sera that contained 30 µg of total protein was taken 141 
from each sample, and submitted to in-solution digestion. Firstly, the volume was adjusted with 0.4 M 142 
NH4HCO3, 1 M Urea, pH 8 to a total volume of 200 µL, and then the QPrEST™- containing peptides were 143 
spiked into the samples at different concentrations depending on the study (see below). The samples 144 
were sonicated for 3 minutes and after that, 10 µL of 45 mM DTT was added and the samples were kept 145 
at 50°C for 15 minutes to reduce the proteins. To irreversibly carbamidomethylate the cysteines, 10 µL of 146 
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100 mM IAA was added, followed by 15 minutes incubation at room temperature in darkness. For the 147 
digestion, 5% (w/w) of trypsin was added and the samples were incubated over night at 37°C. The heavy-148 
labelled synthetic peptide was then spiked into the samples, and they were completely dried in a 149 
SpeedVac system. The samples were re-suspended in 40 µL 0.5% TFA and desalted using the SPE Pierce® 150 
C18 Spin Columns (ThermoFisher Scientific). These columns were activated by 2 x 200 µL of 50% ACN and 151 
equilibrated with 2 x 200 µL of 0.5% TFA. The tryptic peptides were adsorbed to the media using 2 152 
repeated cycles of 40 µL sample loading and the column was washed using 2 × 200 μL 0.5% TFA. Finally, 153 
the peptides were eluted in 2 × 30 μL of 70% ACN and dried. Before they were analysed on a nanoLC-154 
LTQ-Orbitrap mass spectrometer, the peptides were re-suspended in 160 µL of 0.1% FA in Milli-Q water. 155 
NanoLC-Q Exactive Plus-PRM analysis 156 
The PRM analysis was performed on a Q Exactive Plus Orbitrap mass spectrometer (ThermoFisher 157 
Scientific). An EASY-nLC 1000 system (ThermoFisher Scientific) was used for the peptide separation. A 158 
volume of 4 µL of sample was loaded onto a pre-column (EASY-Column, 2 cm, inner diameter 100 µm, 5 159 
µm, C18-A1, ThermoFisher Scientific) at a maximum pressure of 280 bar. The peptides were then eluted 160 
onto an EASY-column, 10 cm, inner diameter 75 µm, 3 µm, C18-A2 (ThermoFisher Scientific), which was 161 
used for the separation. A flow rate of 250 nL/min using mobile phase A (Milli-Q water with 0.1% FA) and 162 
B (ACN with 0.1% FA) was set for the separation. A 40 minutes gradient from 5% B to 40% B followed by 163 
10 minutes from 40% B to 75% B, and a washing step with 10% B for 10 min was used. The system was 164 
controlled through Q Exactive Plus Tune 2.5 and Xcalibur 3.0. The PRM method combined two scan 165 
events starting with a full scan event followed by targeted MS/MS for the doubly and/or triply charged 166 
precursor ion scheduled in an inclusion list. The full scan event employed a m/z 300-800 mass selection, 167 
an Orbitrap resolution of 140,000 at m/z 200, a target automatic gain control (AGC) value of 3*106, and 168 
maximum fill times of 250 ms. The targeted MS/MS was run at an Orbitrap resolution of 35,000 at m/z 169 
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200, target AGC value of 1*106, and maximum fill times of 200 ms. The targeted peptides were isolated 170 
using a 1.2 m/z unit window. MS/MS fragmentation was performed using the high energy collision 171 
dissociation (HCD) mode, with normalized collision energy (NCE) of 27 eV. The mass spectrometry 172 
proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE51 partner 173 
repository with the data set identifier PXD009277. 174 
Determination of linearity, repeatability and limits of detection (LOD) and quantification (LOQ)of the 175 
method 176 
The IGF-II and IGFBP-3 QPrEST™ proteins and the heavy-labelled GPETLCGAELVDALQFVCGDR peptide 177 
were used in a spike-in experiment to determine the linearity and the repeatability of the targeted 178 
proteins, applying the PRM-method. For the calibration curves, the QPrEST™ were spiked into canine 179 
sera to final concentrations of 0.058, 0.29, 1.4, 7.2 and 36 fmol/μL for IGF-II, and 0.019, 0.094, 0.47 and 180 
2.3 fmol/μL for IGFBP-3. The samples were then digested and thereafter, the 181 
GPETLCGAELVDALQFVCGDR peptide was spiked into the sample to final concentrations of 0.0024, 0.012, 182 
0.059, 0.29 and 1.5 fmol/μL. These samples were analysed in triplicate. For the intraday repeatability 183 
study, three serum samples (technical replicates) from the NICTH dog after surgical removal of the 184 
splenic tumor were spiked-in with the QPrEST™ or the heavy GPETLCGAELVDALQFVCGDR peptide the 185 
same day. The concentrations were selected based on the ratios obtained in the calibration curves 186 
between the native and the synthetic peptides, to obtain an approximate ratio of 1. The final 187 
concentrations were 7.2 fmol/μL for IGF-II, and 0.47 fmol/μL for IGFBP-3. These samples were then 188 
digested and the GPETLCGAELVDALQFVCGDR peptide was spiked-in to a final concentration of 0.29 189 
fmol/μL. These samples were analysed in triplicate, and all data were processed together (n=9). For the 190 
interday repeatability study, the same sample preparation was applied as for the intraday repeatability 191 
study, but in this case, serum from the dog before and after the surgery of the splenic tumor was used. 192 
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The same sample was prepared in three different and non-consecutive days, and they were analysed in 193 
triplicate (n=9). For data analysis, the SkyLine 3.7.0 software52 was applied to extract area under curve 194 
(AUC) of the fragments. For the statistical analysis, the built-in tool Data Analysis in Microsoft Excel 195 
Professional 2010 was used. Ordinary least squared regressions along with ANOVA were used to 196 
evaluate the fitness of the calibration curves (one predictive variable), the relation between IGF protein 197 
concentrations and weight (two variables), and the relation between IGF-I concentrations calculated 198 
using the PRM MS-based method and the ELISA method (two variables). To evaluate the effect of the 199 
splenic tumor removal in the concentration of IGF proteins, the normal distribution of the data was 200 
verified by visual examination and by the Anderson-Darling normality test, and a paired sample T-test 201 
was applied. In all these analyses, p-values < 0.05 were considered statistically significant. The LOD and 202 
LOQ for IGF-I, IGF-II and IGFBP-3 were calculated using the following formulas: LOD = 3Sa/b, LOQ = 203 
10Sa/b, where Sa is the standard deviation of the minimum detectable concentration with an RSD ≤ 20%, 204 
and b is the slope of the standard dilution curve.53 LOD for big IGF-II was determined by manual 205 
inspection of analysed samples in the low concentration range, as described in the results. 206 
Method comparison 207 
Measurements of IGF-I is used routinely for diagnosis of GH-related diseases in dogs. Seven samples 208 
were analysed both with MS and an IGF-I ELISA (Mediagnost, Reutlingen, Germany)  previously validated 209 
for use in dogs.54  210 
 211 
RESULTS 212 
Internal standard selection 213 
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The first step for the optimization of the targeted MS-based method used for quantification of IGF-I, IGF-214 
II and IGFBP-3, and the incompletely processed form of IGF-II (big IGF-II), was the selection of the 215 
internal standard. IGF-I protein from dog is well defined in the UniProt database, but IGF-II and IGFBP-3 216 
are classified as “uncharacterized proteins”, with three different identifiers for IGF-II (J9NYS6, F1PBX5 217 
and 9P961) and one identifier for IGFBP-3 (F1PQ91). To study if the human-derived QPrEST™ could be 218 
used as internal standard, the canine sequences of those identifiers were aligned with the human 219 
sequences (Figure 1). The chosen sequences were verified as unique to the targeted proteins.  220 
 221 
Figure 1. Homology study of IGF-I, IGF-II and IGFBP-3 dog proteins and their human analogues (* indicates the same amino acid). The shorter 222 
mature protein is underscored. The tryptic peptides in QPrEST™ or the heavy-labelled synthetic peptide matching peptides found in the canine 223 
sequence and used for quantification are market in bold. In grey, is marked a QPrEST™ tryptic peptide that could be theoretically used for big 224 
IGF-II quantification. 225 
For IGF-I, while the sequences of the pre-processed form differ between both species (195 aa in humans 226 
vs 153 aa in dogs), the mature form of (70 aa) is identical. However, human QPrEST™ proteins that match 227 
this sequence are not available. Therefore, as was done in a previous study with cats,38 a synthetic heavy 228 
isotope-labelled peptide (GPETLCGAELVDALQFVCGDR) was used for the quantification. For IGF-II, the 229 
mature form (67 aa in humans) differs in comparison with the three UniProt canine identifiers, as well as 230 
the E-peptide (or pre-processed) sequence (89 aa in humans). Nevertheless, some regions are conserved, 231 
and the same QPrEST™ used in our previous study was selected. This QPrEST™ protein contains five 232 
tryptic peptides that match well with the three canine IGF-II identifiers. Two of these peptides, 233 
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GIVEECCFR and SCDLALLETYCATPAK, match perfectly with a region of the mature IGF-II. However, when 234 
a shotgun analysis of the QPrEST™ standard was performed, a miss-cleavage in SCDLALLETYCATPAK 235 
peptide but not in GIVEECCFR peptide was observed; therefore the latter was selected to increase the 236 
reliability of the quantification. The other three peptides of the QPrEST™ protein match with 237 
unprocessed forms of IGF-II. Among them, GLPALLR peptide matches with the pro-IGF-II obtained after 238 
the cleavage of a 24 amino acid signal peptide (known as IGF-2[1-156]). However, this peptide was not 239 
found in the shotgun analysis of the QPrEST™ standard. Another peptide is DVSTPPTVLPDNFPR, which 240 
matches with one of the big IGF-II forms (known as big IGF-2[1-87]). In this case, a miss-cleavage of the 241 
peptide was observed in the shotgun analysis, and it was discarded for the quantification. The last 242 
peptide is FFQYDTWK, which matches with the big IGF-II form known as [1-104]. This peptide was found 243 
in the shotgun analysis without any miss-cleavage, therefore it was chosen to quantify the levels of big 244 
IGF-II. For IGFBP-3, the human and the reported canine sequences have the same length (291 aa) but 245 
they differ in 20% of the aa. In spite of these differences, the QPrEST™ contains a tryptic peptide that 246 
matches well with the F1PQ91 identifier, and it was selected for IGFBP-3 quantification. 247 
Method evaluation 248 
The parameters of the Q Exactive Plus Orbitrap MS were similar to those used in our previous study,43 249 
but we also included the analysis of a peptide that matches with the big IGF-II form [1-104]. The final 250 
settings for the method can be found in the material and methods section. The retention times of the 251 
selected peptides were confirmed using a shotgun analysis, and an inclusion list with the native and the 252 
heavy isotope-labelled peptides was included in the PRM-method (see Table 1). For IGF-I and IGF-II 253 
peptides, six MS/MS-fragments were used for quantification, and for big IGF-II and IGFBP-3, three 254 
MS/MS-fragments were used. After the selection of the PRM-method parameters, evaluation of the 255 
linearity, the repeatability and the LOD and LOQ was performed. Linear regression of the normalized 256 
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signals to the internal standard peptides over the entire investigated ranges resulted in determination 257 
coefficients of 0.9997 (p<0.001), 0.9978  (p<0.001) and 0.9983 (p<0.001) for IGF-I, IGFBP-3 and IGF-II 258 
(Figure 2, Raw data and calculations are given in Supporting Table S1). In the case of big IGF-II, linearity 259 
was observed in the range 0.058 - 1.4 fmol/μL, resulting in a determination coefficient of 0.9939 260 
(p<0.001). 261 
 262 
Figure 2. Calibration curves for IGF-I, IGFBP-3, IGF-II and big IGF-II dog proteins. The ratio synthetic/native peptide is plotted against the spiked 263 
concentration. 264 
For the repeatability study, the retention times of the selected peptides, and the quantification based on 265 
the normalized AUC signals were used (Tables 2 and 3, Raw data and calculations are given in Supporting 266 
Table S2). The data indicate that the retention times of IGFBP-3, IGF-II, big IGF-II and IGF-I, were 14, 23, 267 
29 and 40 minutes respectively, and the combination of all data shows a RSD lower than 5%. These 268 
results demonstrate the good repeatability of the method. In terms of quantification, the RSD values 269 
were good for IGF-I and acceptable for the other proteins.  LOD and LOQ were calculated based on a  270 
standard statistical approach (Supplementary Table S1). Due to few calibration points in the linear range 271 
in combination with very low concentrations of big IGF-II in samples from healthy dogs and in the dog 272 
with NICTH after surgery, the LOD of big-IGF-II was estimated based on the observation of well defined 273 
MS/MS-fragments and the standard deviation in the repeatability study (Table 3). In this sample there 274 
were at least two well defined MS/MS-fragments in all intraday measurements and at least one well 275 
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defined fragment in all interday measurements. In addition, we considered RSD on the interday 276 
measurements to be acceptable. The LOD was estimated to be 6.59 fmol/µL. The LOQ was not estimated 277 
for this protein.   278 
Quantification of IGF-I, IGF-II, big IGF-II and IGFBP-3 in dogs 279 
The concentrations of IGF-I, IGF-II, big IGF-II and IGFBP-3 were determined in serum from 7 healthy dogs 280 
(Table 4, Raw data and calculations are given in Supporting Table S3). Due to the low concentrations of 281 
big IGF-II in healthy dogs two healthy dogs were below LOD. All samples were analysed in two replicates 282 
using the developed PRM-method. The measurements gave RSD values similar as those observed in the 283 
repeatability study., As expected based on previous studies,43,44 there was a significant correlation 284 
between weight and IGF-I (r = 0.8526, p<0.05) (Figure 3). There was no correlation between weight and 285 
IGF-II (r = 0.1767, p=0.705) and the trend to a correlation between weight and IGFBP-3 did not reach 286 
statistical significance (r = 0.6617, p=0.105). The IGF-II:IGF-I ratio was inversely correlated to weight (r = - 287 
0.8313, p<0.05). 288 
 289 
Figure 3. Regression curves obtained after plotting the quantified concentrations of IGF-I, IGF-II and IGFBP-3 proteins, and the IGF-II: IGF-I ratio 290 
against the weight of seven dog samples serum. 291 
Method comparison 292 
There was good agreement between IGF-I concentrations calculated using the PRM MS-based method 293 
and the ELISA method (r = 0.9254, p<0.05) (Raw data and calculations are given in Supporting Table S4). 294 
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 295 
Canine case study of NICTH syndrome 296 
A 9-year old male Labrador retriever, weighing 40 kg, was admitted to a large Veterinary Hospital in 297 
Stockholm, Sweden, with sudden ataxia and weakness. At presentation, the dog was unable to stand up 298 
and was treated as an in-house patient. Body temperature, heart and pulmonary auscultation were 299 
normal. No abnormal findings were detected on neurologic exam but postural reactions were difficult to 300 
assess due to difficulties of standing.  301 
Serum and EDTA-blood were submitted to the laboratory for a basic panel. The results revealed 302 
profound hypoglycemia, low insulin concentrations and very mild increase in sodium (Supporting Table 303 
S5). The dog was treated with i.v. fluids containing glucose and despite this there was persistent 304 
hypoglycemia (2.1, 1.2, 1.4 and 3.4 mmol/L, reference interval 3.7-6.6) although the signs of weakness 305 
and ataxia disappeared with glucose infusion. The dog received one injection of prednisolone (1 mg/kg 306 
sc) which was followed by oral administration (1 mg/kg once daily) the next day. Ultrasound revealed an 307 
11 x 15 cm mass in the spleen. There were no abnormal findings in the pancreas. No signs of metastasis 308 
were found on radiographs of lungs. The spleen was removed and sent for histopathology and the dog 309 
was sent home on prednisolone and frequent meals. Histopathology demonstrated a leiomyoma. At re-310 
check one week after the tumor was removed, the dog was euglycemic (5.9 mmol/L) and had no 311 
abnormal clinical signs. Prednisolone was tapered and withdrawn. At recheck 3 months post-surgery, the 312 
dog was still euglycemic and insulin had increased to 200 ng/L which was within reference interval (40-313 
380 ng/L). Based on hypoglycemia and low insulin concentration together with a splenic tumor, NICTH 314 
was suspected. In humans with NICTH, feedback inhibition by increased concentrations of big IGF-II will 315 
usually induce a pattern with low IGF-I and IGFBP-3. The concentrations of IGF proteins were determined 316 
in this dog. As shown in Figure 4, there was a significant increase of IGF-I (from 3.73 to 71.2 fmol/µL, 317 
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p<0.001) and IGFBP-3 (from 73.6 to 315 fmol/µL, p<0.001) between samples taken before and 3 months 318 
after tumor removal off any medications. Concentrations of big IGF-II decreased by 80% (from 35.4 to 319 
6.59 fmol/µL, p<0.001) whereas concentrations of total IGF-II did not change significantly (p=0.85).  320 
 321 
Figure 4. Mean concentration and standard error of the mean of IGF-I, IGFBP-3, IGF-II, big IGF-II proteins in a dog with NICTH syndrome, before 322 
and after the removal of the splenic tumor (*** indicates significant differences after a two-sample T-test, p-value < 0.001). 323 
 324 
DISCUSSION 325 
Measurement of IGF proteins in dogs using RIA, ELISA or WLB possess limitations which may be 326 
overcome using MS-based methodologies.55 In our study, a previously developed PRM-method for cats 327 
has been optimized and applied to quantify four canine members of the IGF system (IGF-I, IGF-II, big IGF-328 
II [1-104] and IGFBP-3) in healthy dogs, and in a dog with NICTH syndrome, a rare paraneoplastic 329 
phenomenon. To the best of our knowledge, this is the first time that simultaneous MS measurements of 330 
the IGF system proteins have been performed in serum from a dog with NICTH, and the first time that 331 
big IGF-II [1-104] has been measured by mass spectrometry in any species. The targeted amino acid 332 
sequences were identical in humans and dogs, and it is therefore possible that the method can also be 333 
applied in humans with NICTH syndrome. 334 
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The developed method allows the measurement of all proteins at the same time, decreasing the 335 
variation due to the methodology (IGFBPs are not interfering in the assay), and reducing the amount of 336 
serum needed for the analysis (less than 1 µL). In addition, the high sensitivity obtained by using a 337 
nanoLC coupled to a high-resolution Q Exactive Plus Orbitrap MS method reduced the tedious and time-338 
consuming sample preparation steps needed to increase the sensitivity of other methods,28,31,32 and 339 
more proteins can easily be added to the list of proteins to be quantified if suitable peptides for 340 
quantification are identified. Moreover, QPrEST™ synthetic proteins were used for the quantification of 341 
IGF-II, IGFBP-3 and big IGF-II, and they were added to the samples prior to the digestion step. As far as 342 
we know, we are the first group using QPrEST™ human proteins to quantify non-human proteins, 343 
previously in cats,43 and now in dogs. QPrEST™ synthetic proteins are well characterized, they are cheap 344 
to produce and purchase, and they offer extensive human proteome coverage. However, the use of 345 
QPrEST™ has the limitation that, in general, fewer tryptic peptides can be selected for quantification. In 346 
the present study, several tryptic fragments were available for IGFBP-3, IGF-II, and big IGF-II 347 
quantification, but only one peptide for each protein met all the requirements needed for a reliable 348 
quantification. In addition, no QPrEST™ proteins were available to target the active sequence of IGF-I, 349 
therefore an isotope-labelled tryptic peptide was used. The peptide chosen for IGF-I quantification 350 
(GPETLCGAELVDALQFVCGDR) has been used in previous works to quantify IGF-I protein in human,28,33,56 351 
and cat samples43 with successful results. This peptide contains a proline in its sequence, which might 352 
induce the “proline effect”, characterized by favouring the cleavage of the N-terminal to proline during 353 
MS/MS fragmentation. However, this effect is mainly observed when the collision-induced dissociation 354 
(CID) fragmentation mode is used and we used the high energy collision dissociation (HCD) 355 
fragmentation mode. HCD has no low-mass cutoff, higher resolution and, because it employs higher 356 
energy dissociations than CID, it enables a wider range of fragmentation pathways. In addition, the 357 
selected peptide contains glutamine, which is prone to deamidation. This modification was observed in 358 
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the preliminary shotgun analysis, but its abundance was very low compared to the unmodified form. In 359 
the case of IGFBP-3, the selected peptide has been used to quantify the levels of IGFBP-3 protein in 360 
cats,43 and our data also demonstrate good linearity and acceptable repeatability based on the RSD 361 
value. The high RSD value could be due to the small amount of this protein in the serum, but also 362 
because of the chemical properties of the peptide used. This peptide is hydrophilic and it can be lost 363 
differentially during the desalting process, or because of the instability of the electrospray at early time 364 
points (it elutes early in the gradient, minute 14, and it has the highest RSD of all peptides used). Some 365 
difficulties have previously been seen when analysing IGFBP-3 protein by mass spectrometry.34 The 366 
authors of that work suggested that the problems could be due to the formation of complexes between 367 
large molecular weight proteins from plasma and IGFBP-3, and they developed a labour intensive sample 368 
preparation protocol including precipitation and delipidation steps to concentrate the targeted proteins. 369 
However, the authors still had accuracy problems for the quantification of IGFBP-3. In the present work, 370 
we aimed to develop a simple and rapid method that require less than 1 μL of serum. The peptide 371 
selected for the quantification of IGF-II has been previously used to quantify the levels of IGF-II protein in 372 
humans,34 and cats,43 and our data also demonstrates good linearity and acceptable repeatability. Finally, 373 
the peptide FFQYDTWK was selected to quantify the levels of big IGF-II form, and this peptide has never 374 
been used either in humans or dogs. 375 
In humans, increased concentration of bioavailable IGF-II can cause negative feedback on pituitary GH 376 
secretion, leading to low IGF-I and IGFBP-3 concentrations.1 Based on that, the recommendation is to 377 
consider the diagnosis of NICTH in a patient if hypoglycemia, suppressed insulin, and low IGF-I 378 
concentrations are found.57 In dogs, at profound low glucose concentrations, insulin should be low or 379 
undetectable20 and this is an important difference when separating NICTH from insulinoma, where 380 
hypoglycemia is accompanied by normal to high insulin concentrations. However, there are to date no 381 
previous case reports of canine NICTH where both insulin and IGF-I have been measured. Therefore, the 382 
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application of the present method to measure the levels of IGFs proteins in a dog with NICTH syndrome 383 
has revealed that IGF-I was decreased, which together with the low insulin levels, suggest the 384 
recommendations made for human NICTH are also applicable in dogs.  385 
Moreover, the ratio of IGF-II:IGF-I >10 has been suggested as an additional marker for diagnosis of NICTH 386 
in humans.57 In our study, the IGF-II:IGF-I ratio was inversely correlated to weight. This may be explained 387 
by differences of the IGF-system. In dogs, we and others22,48,49 have observed that IGF-I concentrations, 388 
but not IGF-II, are strongly associated with body size. This finding will impact the IGF-II:IGF-I ratio. In our 389 
study, the smallest dog (2.4 kg) had an IGF-II:IGF-I ratio of 94, whereas the largest dog (46 kg) had a ratio 390 
of 6. The dog with NICTH syndrome weighed approximately 40 kg and the IGF-II:IGF-I ratio decreased 391 
from 294 to 16 after removal of the tumor. Dogs were of different breeds, ages and gender but 392 
unfortunately there were too few dogs to investigate possible confounding factors. Measurements from 393 
a larger population of healthy dogs of different sizes are needed before any ratio between IGF-II and IGF-394 
I can be recommended as an additional marker for canine NICTH.  395 
Furthermore, in human patients with NICTH, total IGF-II concentrations measured by immunoassays are 396 
reported to be low, within RI or high.1 NICTH in humans is often caused by precursor forms of IGF-II, 397 
usually big IGF-II [1-87] or IGF-II [1-104], and for diagnosis with immunoassays, antibodies targeting 398 
these big forms are needed. Big IGF-II represents at least 10% of total IGF-II in the healthy population,58 399 
and this proportion is increased with NICTH.59 As well as for IGF-II, there are no standard methods to 400 
quantify big IGF-II [1-104] in dogs. Here we present a novel MS-based approach. In serum from the dog 401 
with NICTH, the concentration of the protein before surgery was determined with high confidence and 402 
an RSD value of ≈ 5%) (Table 3). Values decreased considerably after tumor removal and was similar to 403 
healthy dogs. LOD was calculated based on the sample from the dog with NICTH after surgery and was 404 
6.59 fmol/µl. This assumption restricts the calculations of the absolute concentrations in some healthy 405 
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dogs. The low concentrations in healthy dogs and the relatively high RSD seen at low concentrations of 406 
big IGF-II and IGFBP-3 indicates that one should be cautious about interpreting small canges of these 407 
proteins with this method. Based on biological variation of IGF-I in dog, RSD up to 10.5% is considered 408 
desirable and up to 15.7% is considered acceptable.60,61 All the meausurements of IGF-I in the present 409 
study demonstrated an RSD of <12.7%. To the best of our knowledge, there are no expert opinions or 410 
data on biological variation to help determine a clinically acceptable RSD for big IGF-II, IGFBP-3 and total 411 
IGF-II in dogs. Further studies where these proteins are measured in healthy dogs as well as in diseased 412 
dogs are needed to evaluate the clinical usefulness of this method. Before surgery, big IGF-II [1-104] was 413 
only 3.23% of total IGF-II, which is lower than previous reports in human serum. It is possible that other 414 
precursor forms of IGF-II (e.g. big IGF-II [1-87]) are present, and this could explain why big IGF-II [1-104] 415 
was such a small percentage of the total IGF-II. Another interesting aspect is that the sequence used for 416 
quantifying big IGF-II [1-104] is located in the E-peptide region and the cleaved E-peptide can circulate in 417 
serum as well as being a part of big IGF-II.59 In the study by Daughaday and Trivedi, immunoreactivity 418 
against the cleaved IGF-II E-peptide was similar in serum from healthy subjects compared to a NICTH 419 
patient.59  The cleaved E-peptide has been named preptin and found to be co-secreted with insulin by 420 
pancreatic beta-cells.62 There is scarce information about preptin but, as reviewed by Aydin in humans 421 
and rats, it seems to be mainly secreted from pancreas and is positively associated with insulin 422 
concentrations.63 In the dog with NICTH syndrome, undetectable insulin concentrations, and high big 423 
IGF-II [1-104] concentrations were found before surgery, while insulin increased and big IGF-II [1-104] 424 
decreased after surgery. If dogs show the same patterns as humans and rats, most of the measured 425 
sequence is likely to represent big IGF-II. However, further studies are needed to evaluate preptin and its 426 
role in the IGF-system. 427 
 428 
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CONCLUSION 429 
NICTH is a rare paraneoplastic syndrome and should be suspected in dogs with persistent hypoglycemia, 430 
in the presence of low insulin and low IGF-I. High precursor forms of IGF-II would further support 431 
diagnosis. We have developed a PRM MS-based method that allows the simultaneous quantification of 432 
IGF-I, total IGF-II, IGFBP-3 and, for the first time, the quantification of big IGF-II protein in dogs. This 433 
method overcomes the need for antibody availability or potential antigen cross-reactions that are 434 
problems in enzymatic or radioimmunoassays, as well as the tedious and time consuming sample 435 
preparation. It is also adaptable and scalable to detect other biomarkers of interest if suitable peptides 436 
for quantification are identified, and it requires less than 1 μL of serum, making this method potentially 437 
useful for clinical laboratories. Moreover, we have used the heavy-labelled synthetic QPrEST™ proteins 438 
designed for humans, which enable the correction for possible incomplete proteolysis that could affect 439 
the selected peptide and cause variability in the protein quantification. The method was demonstrated 440 
to possess good linearity and repeatability, and has been successfully applied to a dog with NICTH 441 
syndrome, with results in accordance with previous human studies found in the literature. These 442 
measurements may aid in diagnosing NICTH, however further studies with more dogs are needed to 443 
evaluate reference ranges and diagnostic performance of this method.  444 
  445 
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Figure legends 453 
Figure 1. Homology study of IGF-I, IGF-II and IGFBP-3 dog proteins and their human analogues (* 454 
indicates the same amino acid). The shorter mature protein is underscored. The tryptic peptides in 455 
QPrEST™ or the heavy-labelled synthetic peptide matching peptides found in the canine sequence and 456 
used for quantification are market in bold. In grey, is marked a QPrEST™ tryptic peptide that could be 457 
theoretically used for big IGF-II quantification. 458 
Figure 2. Calibration curves for IGF-I, IGFBP-3, IGF-II and big IGF-II dog proteins. The ratio 459 
synthetic/native peptide is plotted against the spiked concentration. 460 
Figure 3. Regression curves obtained after plotting the quantified concentrations of IGF-I, IGF-II and 461 
IGFBP-3 proteins, and the IGF-II:IGF-I ratio against the weight of seven dog serum samples. 462 
Figure 4. Mean concentration and standard error of the mean of IGF-I, IGFBP-3, IGF-II, big IGF-II proteins 463 
in a dog with NICTH syndrome, before and after the removal of the splenic tumor (*** indicates 464 
significant differences after a two-sample T-test, p-value < 0.001).   465 
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Tables 466 
Table 1. Targeted peptides included in the PRM method. 467 
Protein [m/z] (Th) Charge Sequence Position RT (min) Fragments 
IGF-I 769.6963 3+ GPETLCGAELVDALQFVCGDR (light) 1-21 40.3 
y4, y5, y6, y7, y10,b9 
 773.0324 3+ GPETLCGAELVDALQFVCGDR (heavy) 1-21 40.3 
IGF-II 585.2575 2+ GIVEECCFR (light) 41-49 22.5 
y3, y4, y5,y6, y7, b3 
 590.2617 2+ GIVEECCFR (heavy) 41-49 22.5 
big IGF-II 567.7664 2+ FFQYDTWK (light) 90-98 29.4 
y5,y6, y7, 
 571.7735 2+ FFQYDTWK (heavy) 90-98 29.4 
IGFBP-3 506.2136 2+ ETEYGPCR (light) 207-214 14.2 
y2, y4, y5 
 511.2178 2+ ETEYGPCR (heavy) 207-214 14.2 
C-terminal arginine (R) and Lysine (K) of heavy peptides were labelled with (15N , 13C). All cysteines are carbamidomethylated 468 
(underscored). 469 
 470 
Table 2. Intraday repeatability data of the peptides in dog’s serum after surgery. Three serum samples 471 
(technical replicates) were prepared independently and each sample was analysed in triplicate (n=9). 472 
 
Retention time  Quantification 
  Mean (min) RSD (%)  Mean (fmol/µL) SEM (fmol/µL) RSD (%) 
IGF-I 41.0 0.33  79.1 1.08 4.11 
IGF-II 23.1 1.7  977 68.3 19.8 
big IGF-II 30.1 1.1  5.49 0.555 26.7 
IGFBP-3 14.6 2.8  312 34.9 33.6 
 473 
  474 
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Table 3. Interday repeatability data of IGF-peptides in a case of canine NICTH before and after surgery. 475 
The same sample was prepared in three different and non-consecutive days, and they were analysed in 476 
triplicate (n=9). 477 
 
Before surgery, n=9  After surgery, n=9 
 
Retention time Quantification  Retention time Quantification 
  
Mean 
(min) 
RSD 
(%) 
Mean 
(fmol/µL) 
SEM 
(fmol/µL) 
RSD 
(%) 
 Mean 
(min) 
RSD 
(%) 
Mean 
(fmol/µL) 
SEM 
(fmol/µL) 
RSD 
(%) 
IGF-I 40.2 1.6 3.73 0.106 8.08  39.8 2.4 71.2 3.01 12.7 
IGF-II 22.4 3.5 1100 88.7 24.3  22.0 4.2 1120 79.8 21.4 
big IGF-II 29.3 3.0 35.4 0.651 5.20  28.7 4.2 6.59 0.313 14.3 
IGFBP-3 14.2 4.2 73.6 8.69 33.4  13.7 4.9 316 28.6 25.7 
 478 
Table 4. Weight and quantified levels of IGF proteins in 7 different dogs. 479 
 Weight  IGF–I  IGF–II  IGFBP–3  big IGF–II  IGF–II:IGF–I ratio 
 (Kg)  Mean (fmol/µL) 
RSD 
(%) 
 Mean 
(fmol/µL) 
RSD 
(%) 
 Mean 
(fmol/µL) 
RSD 
(%)  
Mean 
(fmol/µL) 
RSD 
(%)  Mean 
RSD 
(%) 
Dog 1 24  39.0 3,70  681 4,92  66,2 28.0  9,68 29,3  17,5 8,61 
Dog 2 24  53.7 0,603  852 8,94  69,5 12,4  13,3 3,95  15,9 8,34 
Dog 3 2.4  3.39 6,19  319 12.0  59,3 51,2  <6.59a -  94,6 18,2 
Dog 4 28  35.0 0,456  773 11,7  133 27.0  11,4 27,2  22,1 11,3 
Dog 5 45  63,6 4,85  410 4,11  522 9,75  15 3,99  6,44 0,738 
Dog 6 35  33,7 1,80  455 1,21  498 10,9  9,48 1,24  13,5 0,587 
Dog 7 15  16,8 0,343  420 3,81   343 1,22   <6.59a -   25.0 3,47 
a Concentration below the estimated LOD.  480 
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